scholarly journals Methodological differences account for inconsistencies in reported free VEGF concentrations in pregnant rats

2014 ◽  
Vol 306 (11) ◽  
pp. R796-R803 ◽  
Author(s):  
Tracey L. Weissgerber ◽  
Andrea McConico ◽  
Bruce E. Knudsen ◽  
Kim A. Butters ◽  
Suzanne R. Hayman ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Plasma Concentrations ◽  
Vascular Endothelial ◽  
Sensitivity Limit ◽  
Pregnant Rats ◽  
Assay Sensitivity ◽  
Rat Models ◽  
Endothelial Growth Factor ◽  
In Pregnancy

Free vascular endothelial growth factor (VEGF) is undetectable in plasma during human pregnancy. However, studies examining pregnant rats have reported both low (8–29 pg/ml) and high (527–1,030 pg/ml) free VEGF. These discrepancies cast uncertainty over the use of rat models to study angiogenic factors in pregnancy and preeclampsia. This study investigates methodological factors that may explain these discrepancies. Plasma VEGF in nonpregnant, day 7 pregnant, and day 19 pregnant rats was measured using rat and mouse ELISAs (R&D Systems). The rat ELISA detected VEGF in plasma from nonpregnant rats but not in plasma from day 19 pregnant rats. The mouse ELISA detected higher VEGF concentrations than the rat ELISA in every sample tested. This discrepancy was greater in day 19 pregnant rats (median: 2,273 vs. 0 pg/ml) than in nonpregnant (97 vs. 20 pg/ml) and day 7 pregnant (66 vs. 2 pg/ml) rats. Recovery of recombinant rat VEGF (rrVEGF) spiked into plasma from nonpregnant and day 7 pregnant rats was high for the rat ELISA (82–105%) but low for the mouse ELISA (17–22%). The rat ELISA did not recover rrVEGF in plasma from day 19 pregnant rats, suggesting that this ELISA measures free VEGF. The use of the rat versus mouse ELISA likely explains the differences in reported VEGF concentrations in pregnant rats. While the rat ELISA appears to measure free VEGF, plasma concentrations in nonpregnant and pregnant rats are below the assay sensitivity limit. As most previous studies of pregnant rats used the mouse VEGF ELISA, these data should be interpreted cautiously.

scholarly journals Sodium hydrosulfide prevents hypertension and increases in vascular endothelial growth factor and soluble fms-like tyrosine kinase-1 in hypertensive pregnant rats

2016 ◽  
Vol 389 (12) ◽  
pp. 1325-1332 ◽  
Author(s):  
Jose Sergio Possomato-Vieira ◽  
Victor Hugo Gonçalves-Rizzi ◽  
Tamiris Uracs Sales Graça ◽  
Regina Aparecida Nascimento ◽  
Carlos A. Dias-Junior
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Tyrosine Kinase ◽  
Vascular Endothelial ◽  
Pregnant Rats ◽  
Sodium Hydrosulfide ◽  
Endothelial Growth Factor

Vascular endothelial growth factor serum levels in pregnancy and preeclampsia

2000 ◽  
Vol 79 (1) ◽  
pp. 77-78 ◽  
Author(s):  
LUKAS HEFLER ◽  
ANDREAS OBERMAIR ◽  
PETER HUSSLEIN ◽  
CHRISTIAN KAINZ ◽  
CLEMENS TEMPFER
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Serum Levels ◽  
Vascular Endothelial ◽  
Endothelial Growth Factor ◽  
In Pregnancy

scholarly journals Plasma Concentrations of Vascular Endothelial Growth Factor and Basic Fibroblast Growth Factor in Lymphoproliferative Disorders

2005 ◽  
Vol 48 (1) ◽  
pp. 57-58 ◽  
Author(s):  
Lukáš Smolej ◽  
Ctirad Andrýs ◽  
Vladimír Maisnar ◽  
Luděk Pour ◽  
Jaroslav Malý
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Basic Fibroblast Growth Factor ◽  
Plasma Concentrations ◽  
Enzyme Linked Immunosorbent Assay ◽  
Control Group ◽  
Vascular Endothelial ◽  
Fibroblast Growth ◽  
Endothelial Growth Factor

Angiogenesis plays a major role in the development and progression of haematological malignancies. In our study we measured plasma concentrations of key angiogenic activators vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) using comercially available sandwich enzyme-linked immunosorbent assay (ELISA) in 37 patients with lymphoid malignancies and 20 healthy donors. We found a statistically significant increase in bFGF concentrations in patients with B-cell chronic lymphocytic leukemia (B-CLL, n=18) compared to the control group (median 118.8 vs. 9.3 pg/ml, p<0.001). However, we didn’t find any significant difference in VEGF concentrations between B-CLL patients and the control group. There was also no significant increase in bFGF or VEGF in patients with multiple myeloma (n=7) and non-Hodgkin’s lymphoma (n=12). Our pilot study shows that measurement of angiogenic activators in plasma is a feasible and reproducible method of angiogenesis assessment. Larger studies are needed for correlation between serum and plasma concentrations and detailed statistical evaluation including the impact on patients’ survival.

Predictive value of changes in plasma vascular endothelial growth factor at eight weeks after lenvatinib administration in patients with unresectable hepatocellular carcinoma.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. 4594-4594
Author(s):  
Kaoru Tsuchiya ◽  
Masayuki Kurosaki ◽  
Shun Kaneko ◽  
Yutaka Yasui ◽  
Sakura Kirino ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Vascular Endothelial Growth Factor ◽  
Overall Survival ◽  
Growth Factor ◽  
Objective Response ◽  
Plasma Concentrations ◽  
Vascular Endothelial ◽  
Vegf Inhibitors ◽  
Unresectable Hepatocellular Carcinoma ◽  
Endothelial Growth Factor

4594 Background: Lenvatinib (LEN) has been used in patients with unresectable hepatocellular carcinoma (u-HCC) and there is no established predictive biomarker. Previously it was reported that a plasma vascular endothelial growth factor (VEGF) concentration decrease at 8 weeks after starting sorafenib might predict favorable overall survival (OS) in patients with u-HCC (Tsuchiya, et al. Cancer, 2013). We aimed to investigate the value of changes in plasma VEGF at 8 weeks after LEN administration in patients with u-HCC. Methods: Forty-six patients with u-HCC who received LEN between April 2018 and August 2019 at our institution were enrolled. Plasma concentrations of VEGF and serum α-fetoprotein (AFP) levels were measured at baseline, 4 and 8 weeks after administration of LEN. A VEGF decrease was defined as > 5% decrease during 8 weeks after the beginning of LEN therapy. AFP response was defined as > 20% decrease during 8 weeks according to the previous reports. Results: Median overall survival (OS) was not reached and progression-free survival (PFS) was 5.9 months. Median observation period and treatment duration were 10.1 and 6.3 months. The objective response rate and disease control rate by mRECIST criteria were 43.5% and 82.6%. Median PFS in patients who had a VEGF decrease at week 8 (n = 29) was significantly longer than those who did not have a VEGF decrease (n = 17; 7.1 months vs 5.0 months; p = 0.014). AFP response was not associated with PFS. There were no significant differences in baseline VEGF, AFP, ALBI score, and extrahepatic metastasis between the patients with and without a VEGF decrease. A VEGF decrease was significantly associated with radiological objective response (p = 0.001) and 18 of 20 patients who achieved CR (n = 3) or PR (n = 17) had a VEGF response in LEN therapy. Conclusions: A decrease of plasma VEGF level at 8 weeks in patients with u-HCC on LEN was significantly associated with PFS. Changes in plasma VEGF could become a new biomarker for molecular targeted therapies including VEGF inhibitors in patients with unresectable HCC.

scholarly journals Vascular endothelial growth factor expression in placenta of hypertensive disorder in pregnancy

2017 ◽  
Vol 60 (4) ◽  
pp. 515 ◽  
Author(s):  
GeokChin Tan ◽  
AbdFuaat Azliana ◽  
MohamadRazi Zainul-Rashid ◽  
SabrinaFlorence Chandramaya ◽  
WirdaIndah Farouk ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Hypertensive Disorder ◽  
Vascular Endothelial ◽  
Factor Expression ◽  
Growth Factor Expression ◽  
Endothelial Growth Factor ◽  
In Pregnancy
Sign in / Sign up

Export Citation Format

Share Document